Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.

DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, Crowley D, Chen J, Jacks T.

Cancer Cell. 2011 Jan 18;19(1):72-85. doi: 10.1016/j.ccr.2010.11.011.

2.

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ.

J Immunol. 2003 Nov 15;171(10):5051-63.

3.

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y, Yagita H, Chandler P, Munn DH, Mellor A, Fu N, He Y.

J Immunol. 2010 Nov 1;185(9):5082-92. doi: 10.4049/jimmunol.1001821. Epub 2010 Oct 6.

4.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

5.

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.

Thompson ED, Enriquez HL, Fu YX, Engelhard VH.

J Exp Med. 2010 Aug 2;207(8):1791-804. doi: 10.1084/jem.20092454. Epub 2010 Jul 26.

6.

Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.

Meyer zu Hörste G, Heidenreich H, Mausberg AK, Lehmann HC, ten Asbroek AL, Saavedra JT, Baas F, Hartung HP, Wiendl H, Kieseier BC.

Neurobiol Dis. 2010 Feb;37(2):483-90. doi: 10.1016/j.nbd.2009.11.006. Epub 2009 Nov 13.

PMID:
19914379
7.

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H.

Cancer Immunol Res. 2013 Aug;1(2):123-33. doi: 10.1158/2326-6066.CIR-13-0058.

8.

Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.

Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E.

Int J Cancer. 2012 Sep 1;131(5):E649-58. doi: 10.1002/ijc.27359. Epub 2012 Jan 3.

9.
10.

Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.

Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson B.

J Immunol. 2001 May 1;166(9):5557-66.

11.

Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.

Kemp RA, Ronchese F.

J Immunol. 2001 Dec 1;167(11):6497-502.

12.

Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.

Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M.

Cancer Immunol Immunother. 2014 Apr;63(4):321-33. doi: 10.1007/s00262-013-1510-y. Epub 2014 Jan 3.

PMID:
24384835
13.

Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.

Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC, McArdle SE.

Eur J Immunol. 2014 Apr;44(4):994-1004. doi: 10.1002/eji.201343863. Epub 2014 Mar 7.

14.
15.

Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.

Robson NC, Donachie AM, Mowat AM.

Eur J Immunol. 2008 May;38(5):1238-46. doi: 10.1002/eji.200737758.

16.

Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes.

Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP.

Science. 2008 Jan 11;319(5860):215-20. doi: 10.1126/science.1148886.

17.

Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.

Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, Ronchese F.

Cancer Immunol Immunother. 2008 Nov;57(11):1665-73. doi: 10.1007/s00262-008-0487-4. Epub 2008 Mar 1.

PMID:
18311487
18.

Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.

Oizumi S, Strbo N, Pahwa S, Deyev V, Podack ER.

J Immunol. 2007 Aug 15;179(4):2310-7.

19.
20.

Supplemental Content

Support Center